Home / Going-concern warnings / Armata Pharmaceuticals, Inc.
Filed 2026-03-25 路 Form 10-K 路 Accession 0001104659-26-034532 small
Price before filing: $8.21 (2026-03-24 close, split/dividend-adjusted)
Market cap at flag: $398.6M (2026-03-25) 路 Latest: $123.8M (2026-10-16)
| Window | ARMP | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +57.4% | +9.3% | +48.1% | 2026-04-24 |
| 90 days | -14.6% | +12.6% | -27.2% | 2026-06-23 |
| 180 days | -48.1% | +19.0% | -67.1% | 2026-09-21 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These circumstances raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-K (period 2025-12-31)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.